Shares of biopharmaceutical company Hookipa Pharma (NASDAQ:HOOK) are soaring today on the back of its licensing deal with Roche for HB-700 and a novel immunotherapy (undisclosed).
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
With this move, Hookipa gains an upfront payment of $25 million, a potential optional payment of $15 million for another candidate as well as milestone payments of up to $930 million (apart from sales royalties).
Shares are now up ~24.4% over the last five days.
Read full Disclosure
